Bumetanide | Solubility of Things

Identification

Molecular formula

C₁₇H₂₀N₂O₅S

CAS number

28395-03-1

IUPAC name

3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid

State

Bumetanide is typically a solid at room temperature, often distributed as a crystalline powder. This stability in solid form facilitates its handling and formulation in pharmaceutical applications.

Melting point (Celsius)

233.00

Melting point (Kelvin)

506.15

Boiling point (Celsius)

303.80

Boiling point (Kelvin)

576.95

General information

Molecular weight

364.42g/mol

Molar mass

364.4190g/mol

Density

1.2356g/cm³

Appearence

Bumetanide appears as a white to off-white crystalline powder. Its crystalline nature is evident in its structure and texture that can exhibit a slightly granular appearance typical of crystalline substances.

Comment on solubility

Solubility of 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid

The solubility of 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid (C₁₇H₂₀N₂O₅S) can be influenced by several factors, reflecting its complex structure. Key considerations include:

Polarity: The presence of polar functional groups, such as the sulfamoyl and carboxylic acid moieties, generally increases solubility in polar solvents like water.
Hydrophobic Interactions: The butylamino and phenoxy groups contribute hydrophobic regions that may limit solubility in purely aqueous environments.
pH Levels: The solubility of the carboxylic acid group can be enhanced in basic conditions, where it ionizes, forming a carboxylate anion.
Solvent Nature: Solubility may be higher in organic solvents like ethanol or DMSO compared to water due to the compound’s overall mixed hydrophilic and hydrophobic characteristics.

To summarize, the solubility of this compound is a balance between its polar and non-polar characteristics. As noted, the key is in understanding that:

"A compound's solubility is greatly affected by the interplay of its functional groups and the solvent environment."

This means it may exhibit variable solubility depending on the conditions, making it essential to consider the specific application and solvent when working with 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid.

Interesting facts

Interesting Facts about 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid

This compound is a fascinating example of a sulfonamide derivative that has gained attention in medicinal chemistry. Here are some key points that make this compound particularly interesting:

Pharmacological Potential: Compounds like this often exhibit significant biological activities, making them valuable in drug discovery and development. They can serve as leads for developing treatments for various diseases.
Structural Features: The intricate structure, which includes a sulfonamide group, a carboxylic acid, and an amino group, contributes to its unique properties and reactivity.
Therapeutic Applications: Many sulfonamide derivatives have been used as antibiotics and in treatments for chronic conditions; this compound may share similar applications.
Research Interest: Chemists are continuously exploring compounds like this to understand their mechanisms of action and improve their efficacy and safety profiles.

Quote from a notable chemist: "Understanding the subtle interplay of molecular structure and biological activity can lead to groundbreaking innovations in pharmaceuticals."

The exploration of this compound opens up several avenues for research, including its potential efficacy against specific targets in disease pathways, making it a pivotal subject in the realm of organic and medicinal chemistry.

Synonyms

bumetanide

28395-03-1

3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid

Bumex

Burinex

Fordiuran

Lunetoron

Fontego

Segurex

Bumetanida

Ro 10-6338

Bumetanidum

Aquazone

Butinat

Cambiex

Diurama

Yurinex

Lixil-Leo

3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid

Bumetanidum [INN-Latin]

PF 1593

Bumetanida [INN-Spanish]

Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-

UNII-0Y2S3XUQ5H

EINECS 249-004-6

0Y2S3XUQ5H

BRN 2185351

CHEBI:3213

Ro-10-6338

DTXSID5022699

Bumethanide

BENZOIC ACID, 3-(BUTYLAMINO)-4-PHENOXY-5-SULFAMOYL-

MFCD00078949

3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid

3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid

Ro-106338

MLS000028457

DTXCID702699

Burine

3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid

S95008.

S-95008.

NSC 758145

Bumetanide [USAN:USP:INN:BAN:JAN]

NCGC00015149-02

SMR000058418

Lixil

CAS-28395-03-1

Ro 10-6338;PF 1593

Bumetanidum (INN-Latin)

Bumetanida (INN-Spanish)

BUMETANIDE (MART.)

BUMETANIDE [MART.]

BUMETANIDE (USP-RS)

BUMETANIDE [USP-RS]

BUMETANIDE (EP IMPURITY)

BUMETANIDE [EP IMPURITY]

BUMETANIDE (EP MONOGRAPH)

BUMETANIDE [EP MONOGRAPH]

Bufenox

BUMETANIDE (USP MONOGRAPH)

BUMETANIDE [USP MONOGRAPH]

C17H20N2O5S

Bumetanide (USAN:USP:INN:BAN:JAN)

Bumex (TN)

SR-01000003062

Bumetanide?

Bumetanide (Ro 10-6338)

Bumetanide in bulk

82U

Bumetanide; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-; Benzoic acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl- (8CI); 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-ph

Prestwick_679

Bumetanide (Standard)

Spectrum_001317

Bumetanide, >=98%

BUMETANIDE [MI]

BUMETANIDE [INN]

BUMETANIDE [JAN]

Opera_ID_1734

Prestwick0_000276

Prestwick1_000276

Prestwick2_000276

Prestwick3_000276

Spectrum2_001050

Spectrum3_001481

Spectrum4_000030

Spectrum5_001212

BUMETANIDE [USAN]

Lopac-B-3023

BUMETANIDE [VANDF]

B 3023

cid_2471

BUMETANIDE [WHO-DD]

CHEMBL1072

Lopac0_000162

SCHEMBL27525

BSPBio_000152

BSPBio_001508

BSPBio_003061

KBioGR_000228

KBioGR_000439

KBioSS_000228

KBioSS_001797

3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid

MLS001148265

DivK1c_000034

SPECTRUM1502004

SPBio_000980

SPBio_002371

BPBio1_000168

Bumetanide (JP18/USP/INN)

GTPL4837

BUMETANIDE [ORANGE BOOK]

BDBM25903

HMS500B16

KBio1_000034

KBio2_000228

KBio2_001797

KBio2_002796

KBio2_004365

KBio2_005364

KBio2_006933

KBio3_000455

KBio3_000456

KBio3_002561

C03CA02

NINDS_000034

3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid

Bio1_000421

Bio1_000910

Bio1_001399

Bio2_000228

Bio2_000708

HMS1361L10

HMS1568H14

HMS1791L10

HMS1921B20

HMS1989L10

HMS2089P13

HMS2092N03

HMS2095H14

HMS2230P15

HMS3259O08

HMS3260B05

HMS3374E02

HMS3402L10

HMS3654B13

HMS3712H14

HMS3873C13

Pharmakon1600-01502004

BCP28485

MSK10495

Tox21_110088

Tox21_500162

CCG-40125

HY-17468R

NSC758145

s1287

AKOS015896600

Tox21_110088_1

AC-8115

CS-1821

DB00887

FB19354

KS-5211

LP00162

NC00550

NSC-758145

SDCCGSBI-0050150.P004

IDI1_000034

IDI1_033978

SMP1_000049

NCGC00015149-01

NCGC00015149-03

NCGC00015149-04

NCGC00015149-05

NCGC00015149-06

NCGC00015149-07

NCGC00015149-08

NCGC00015149-09

NCGC00015149-10

NCGC00015149-11

NCGC00015149-12

NCGC00015149-13

NCGC00015149-15

NCGC00015149-16

NCGC00015149-26

NCGC00022072-03

NCGC00022072-04

NCGC00022072-05

NCGC00022072-06

NCGC00022072-07

NCGC00022072-08

NCGC00260847-01

1ST10495

HY-17468

SBI-0050150.P003

AB00052253

EU-0100162

NS00009049

SW196834-3

D00247

EN300-122330

3-butylamino-4-phenoxy-5-sulphamyl-benzoic acid

AB00052253-15

AB00052253-16

AB00052253_17

AB00052253_18

3-n-butylamino-4-phenoxy-5-sulfamyl-benzoic acid

3-n-butylamino-4-phenoxy-5-sulphamyl-benzoic acid

Q275926

SR-01000003062-2

SR-01000003062-4

SR-01000003062-7

BRD-K38197229-001-06-7

BRD-K38197229-001-17-4

BRD-K38197229-001-28-1

BRD-K38197229-001-29-9

3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-benzoic acid

Z1541758727

3-(BUTYLAMINO)-4-PHENOXY-5-SULFAMOYLBENZOIC ACID.

Bumetanide, British Pharmacopoeia (BP) Reference Standard

Bumetanide, European Pharmacopoeia (EP) Reference Standard

Bumetanide, United States Pharmacopeia (USP) Reference Standard

Ro 10-6338; PF 1593 pound>>Ro-10-6338; PF1593 pound>>Ro10-6338; PF-1593

249-004-6

3-(Aminosulfonyl)-5-(butylamino)-4-phenoxy-benzoic acid;3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid;Bufenox